Skip to main content

Phase 2 study of ET-743 as second or third line therapy in advanced and/or metastatic soft tissue sarcoma patients

Phase 2 study of ET-743 as second or third line therapy in advanced and/or metastatic soft tissue sarcoma patients


CSR Summary

Not Yet Available


NCT Number

Not Available


Primary Citation

Not Yet Available


Data Specification

Not Available


Annotated CRF

Not Available

Data Request Dashboard

Operations

No data requests found. Click here to generate a new one.

Product Info

Generic Name
Trabectedin
Product Name
YONDELIS®
Therapeutic Area
Cancers and Other Neoplasms
Enrollment
34
% Female
N/A
% White
N/A
Product Class
Antineoplastic Agents
Sponsor Protocol Number
ET-B-017-99
Data Holder
Johnson & Johnson
Condition Studied
Sarcoma
Mean/Median Age (Years)
N/A

Supporting Documentation

Data Definition Specification Available
Annotated Case Report Form Available
Clinical Study Report
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
2
Additional Information: 

Please note: individual participant-level data are not available for this trial. Only the annotated CRF, protocol, statistical analysis plan, and full clinical study report are available.

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.